Suppr超能文献

FAM136A 免疫反应与中国病例系列中肺腺癌的淋巴结受累和生存相关。

FAM136A immunoreactivity is associated with nodal involvement and survival in lung adenocarcinoma in a Chinese case series.

机构信息

First Department of Head and Neck Surgery, The Third Affiliated Hospital of Kunming Medical University, Tumor Hospital of Yunnan Province, Kunming, Yunnan, 650118, P.R. China.

Department of Cancer Biotherapy Center, Tumor Hospital of Yunnan Province, Kunming, Yunnan, 650118, P.R. China.

出版信息

Bioengineered. 2020 Dec;11(1):261-271. doi: 10.1080/21655979.2020.1735611.

Abstract

Lung cancer patients with lymph node metastasis usually had short overall survival and occurred distant metastases at the early stage. However, some of these people did have more prolonged survival. The underlying reason is still unclear. In this study, we found a novel molecule, family with sequence similarity 136, member A gene (FAM136A). First, we performed immunohistochemistry for FAM136A in 177 lung carcinoma tissues. Second, we carried out studies by using A549 and PC-9. We detected FAM136A immunoreactivity in 79 out of 177 (44.6%) lung carcinoma tissues, and the FAM136A status was significantly associated with tumor T stage, lymph node metastasis, and the Tumor-Node-Metastasis (TNM) staging system in these cases. Importantly, it was significantly associated with the overall survival of the patients with lymph node metastasis, especially FAM136A positive patients, who had worse outcomes. Subsequent experiments revealed that the proliferation activity and migration property decreased both A549 and PC-9 lung carcinoma cells transfected with siRNA-FAM136A, and apoptosis reduced. Meanwhile, the expression of CDK4 and CDK6 decreased. FAM136A status would be a potent, worse prognostic factor in lung cancer patients with lymph node metastasis. It would play a vital role in the proliferation, apoptosis, and migration properties of A549 and PC-9. In the future, We will focus on the uncovered signal mechanism between FAM136A and lung cancer.

摘要

肺癌患者发生淋巴结转移通常总生存期较短,且早期发生远处转移。然而,其中一些人的生存时间确实更长。其潜在的原因尚不清楚。在这项研究中,我们发现了一种新的分子,家族与序列相似性 136,成员 A 基因(FAM136A)。首先,我们对 177 例肺癌组织进行 FAM136A 的免疫组织化学染色。其次,我们使用 A549 和 PC-9 进行了研究。我们在 177 例肺癌组织中的 79 例中检测到 FAM136A 免疫反应性,并且 FAM136A 状态与肿瘤 T 分期、淋巴结转移以及这些病例的肿瘤-淋巴结-转移(TNM)分期系统显著相关。重要的是,它与淋巴结转移患者的总生存率显著相关,尤其是 FAM136A 阳性患者,其预后更差。随后的实验表明,转染 siRNA-FAM136A 的 A549 和 PC-9 肺癌细胞的增殖活性和迁移特性均降低,而凋亡减少。同时,CDK4 和 CDK6 的表达降低。FAM136A 状态将成为淋巴结转移的肺癌患者强有力的预后不良因素。它在 A549 和 PC-9 的增殖、凋亡和迁移特性中发挥重要作用。在未来,我们将专注于未被揭示的 FAM136A 与肺癌之间的信号机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7449/7051133/f84b8765e764/kbie-11-01-1735611-g002.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验